U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07219589) titled 'A SAD Study of HM17321 in Healthy Adult Participants' on Oct. 16.
Brief Summary: This is a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of HM17321 after single ascending doses in healthy adult participants.
Study Start Date: Dec., 2025
Study Type: INTERVENTIONAL
Condition:
Obesity
Obese
Intervention:
DRUG: HM17321
Participants will receive a single subcutaneous injection of HM17321 at the assigned dose level. HM17321 is provided as a sterile solution in prefilled syringes.
DRUG: Placebo of HM17321
Participants will receive a single subcutaneous injection of a matching placebo so...